Some clinicians prefer tapering the first drug and allowing a washout period before starting the second
This review article aims at discussing the potential of therapeutic GLP-1 receptor agonists in alleviating depressive symptoms in the context of modern theories surrounding the pathogenesis of this disease and explores their influence on cognitive processes, neurotransmission, modulation of neuroinflammatory processes, effects on HPA axis activity, brain energy balance, and the functioning of the gut-brain axis
Projections suggest cumulative revenue could reach $470 billion by 2030, positioning these treatments among the best-selling pharmaceutical products in history [38]
The baseline characteristics were 42% with hypertension, 19% with type 2 diabetes, 43% with dyslipidemia, 28% with a BMI greater than 40 kg/m2, and 4% with cardiovascular disease
The effects fade gradually over several weeks
What about other medicines people compare